<SEC-DOCUMENT>0001193125-24-180005.txt : 20240717
<SEC-HEADER>0001193125-24-180005.hdr.sgml : 20240717
<ACCEPTANCE-DATETIME>20240717074727
ACCESSION NUMBER:		0001193125-24-180005
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240717
FILED AS OF DATE:		20240717
DATE AS OF CHANGE:		20240717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241120972

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d779880d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as July 17, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d779880dex991.htm">Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 17, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d779880dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g779880page5.jpg" ALT="LOGO" STYLE="width:2.15625in;height:0.752778in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Receives
Regulatory Clearance for Phase I Study of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">LAG-3</FONT> Agonist Antibody Designed to Treat Autoimmune Diseases </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Study expected to enrol first participants during Q3 CY2024 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 17</B><B></B><B>&nbsp;July </B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics
and&nbsp;competent authority&nbsp;in the Netherlands to initiate the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase I study of IMP761. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761 is the world&#146;s first therapeutic <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody and as such is uniquely positioned in the
treatment landscape for autoimmune diseases. The immune checkpoint <FONT STYLE="white-space:nowrap">LAG-3</FONT> has been identified as a promising target for agonist immunotherapy to treat rheumatoid arthritis, Type 1 diabetes, and multiple
sclerosis, among other autoimmune diseases.<SUP STYLE="font-size:75%; vertical-align:top">1,2,3</SUP> IMP761 is designed to restore balance to the immune system by enhancing the &#147;brake&#148; function of
<FONT STYLE="white-space:nowrap">LAG-3</FONT> to silence unregulated self-antigen-specific memory T cells. These T cells accumulate at disease sites and are the underlying cause of many autoimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Bent Deleuran, MD, Department of Biomedicine, Aarhus University (DK) stated, &#147;Immune checkpoint molecules such as <FONT
STYLE="white-space:nowrap">LAG-3</FONT> play pivotal roles in determining the outcome of antigen activation, and as a result hold significant potential in the treatment of autoimmune diseases. In preclinical studies, the agonistic <FONT
STYLE="white-space:nowrap">LAG-3</FONT> antibody IMP761 has shown, both in vitro and in vivo, to be highly effective in suppressing antigen-specific T cell&#150;mediated immune responses and driving a meaningful decrease in inflammatory cytokines.
It is exciting to see IMP761 move into the clinical setting to evaluate the potential of this new immunotherapy to address autoimmune diseases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The regulatory and ethical clearance for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of
IMP761 is a significant milestone for Immutep and marks an important step in the development of this novel autoimmune disease approach,&#148; said Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, Immutep&#146;s CSO. &#147;Blocking <FONT
STYLE="white-space:nowrap">LAG-3</FONT> with an antagonist antibody in cancer patients unleashes the power of the anti-tumor T cell responses, but also leads to autoimmunity in a fraction of the patients. This has put
<FONT STYLE="white-space:nowrap">LAG-3</FONT> at the center of autoimmune disorders as a <FONT STYLE="white-space:nowrap">co-inhibitory</FONT> receptor that downplays the T cell receptor response. Using IMP761, an agonist <FONT
STYLE="white-space:nowrap">LAG-3</FONT> antibody, to reinforce this physiological upstream control of the T cell response represents a new approach to silence the few aggressive T cells that lead to autoimmune diseases,&#148; added Dr.&nbsp;Triebel.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The single and multiple ascending dose, placebo-controlled, double-blind, Phase I study is being conducted by the <U>Centre for Human Drug Research
(CHDR)</U>, a world-class institute in Leiden, the Netherlands specializing in cutting-edge early-stage clinical drug research. The study aims to enrol 49 healthy volunteers, with the objective of assessing safety, pharmacokinetics (PK) and
pharmacodynamics (PD). CHDR will implement its unique keyhole limpet haemocyanin (KLH) challenge model allowing for the evaluation of IMP761&#146;s pharmacological activity at the earliest stages of clinical development. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g779880page5.jpg" ALT="LOGO" STYLE="width:2.15625in;height:0.752778in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep anticipates that CHDR will enrol first participants into the Phase I study during Q3 of CY2024 with
first data being available before end of the year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive
<FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the
immune system. As published in the <U>Journal of Immunology,</U> encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT> <I>in vivo </I>and<I> in vitro</I> studies show IMP761 inhibits peptide-induced T cell proliferation, activation of
human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction. Additional preclinical data in oligoarticular juvenile idiopathic arthritis <FONT STYLE="white-space:nowrap">(o-JIA)</FONT> published in
<U>Pediatric&nbsp;Research</U> details how IMP761 led to a decrease in a broad spectrum of effector cytokines in just 48&#8201;hours. This study also showed children with <FONT STYLE="white-space:nowrap">o-JIA</FONT> have a skewed <FONT
STYLE="white-space:nowrap">LAG-3</FONT> metabolism and suggested they can benefit from agonistic <FONT STYLE="white-space:nowrap">LAG-3</FONT> activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>c.strong@morrowsodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1. Pedersen, J.M., Hansen, A.S., Skej&oslash;, C. et al. Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis.
Arthritis Res Ther 25, 97 (2023). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1186/s13075-023-03073-z</FONT></FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2. Jones BE, Maerz MD et al. Fewer <FONT STYLE="white-space:nowrap">LAG-3+</FONT> T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. J
Immunol. 2022 Feb <FONT STYLE="white-space:nowrap">1;208(3):594-602.</FONT> doi: 10.4049/jimmunol.2100850. Epub 2022 Jan 12. PMID: 35022272; PMCID: PMC8820445. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>3. Zhou X, Gu Y et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases. Inflamm Res. 2023
Jun;72(6):1215-1235. doi: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1007/s00011-023-01742-y.</FONT></FONT></FONT> Epub 2023 Jun 14. PMID: 37314518. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g779880page5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g779880page5.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MG%>HE=)K;H?4*+:34E9[#BRKU(7Z\8Q_G_.*0"J01QT'U&,>Q]J %H * "@
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M'Q?KT=C#J>J2ZN)XM-AFM[-$L=8OK&!8HIYYG4^1;Q[BTC9;)'!P #UR@ H
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M-1U/J^(B^9:<S[HZ,DXCQDL4L#F4$G%N+G?7F6B73<]0^.GCWQ#X"\.:7?\
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M]JG_ )&CPU_V )/_ $OFKP<Z_C8?T?YL_.>,_P#?,/\ X7^;/<O%G_)O\O\
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M-J *"!D"L)X:A.2E45VMNASXC+<!BJJK5:/M*D=GVL=ND2QHL2@A%4(%QP%
MP .<\#BNE)*/*MDK7OT.Q1IQA[)4FH)6M?H<5HOPU\$>'-276-$\/V6G:FBS
M*EW"9_,"S@K,,/,PPP)R,?E7-3PU"G-SI1Y9=;?UIY]SCH9;@,+6^L4J'LJC
MW?<[*ZLK6^MIK.]MX+NTN(G@N+6YACN+>>&12LD4T,JLDL;+P592".,5T]NE
MCO6C?;H>#WO[+7P,O;F2ZE\$I#)(Y=DL];\0V-N"QR1';6FK1Q0IGHL:JJC
M    7Z#_ $.D\-? 7X1^$KNWOM$\#Z/#?6<T5S:7EX+K5KJUN('62&XMIM7N
M;EK>>-U#*\91E8;@<T;?(-OD>KW%I;W=M-9W4,-S;7$3P7%O<1)-!/#(I22&
M:*0,LL3H2K*P(()!SF@#P>__ &7?@;J%U)=R^!X()97+R)8:OK^G6Q9CN.RS
ML=5BAA7/18T4#L!0!ZEX/\!^$O &G-I7A#0['0["2033Q6B.TES*J>6LMW=3
MR23WDRH H>:20A0 ,"C;R#;R$\6^ O"'CNR33_%V@:=KEM [26XO(3YUK(X
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MDB79$][86MT\2Y)VHT\3E%RS'"D=: +D=K#")1%&D?GOYLQ2-$,DA1(S))M
MWN4C1=QR<(H[4 4KG0])O8(+2\TW3[JUMMOV>UN;*VGM[<HNR/R(I8V6$*F5
M 0+@' P.* -"*WAMX$MH8HX8(D6..&*-(XHXT 5(TB0!415     QP!0!3L-
M'TO2S(=-T^RL/.8/,ME:6]J)G 8!I1!$OF$;CC<3C\\@%MK>)I%F*(9D1XTE
M* R)'(8VDC1^JQN8HBR@@,8D)SM& !HM+=8!:K%&MN%,?D"-!$8V!#1^6%V[
M"&/&,4 *EK!$ZR)%&KI%Y".$0,D(*D0HP'RQ JORCCY1Z4 *MM"CR2K&BR2*
MJR2!%$CJFXHLC@9<+O?&<XW-CJ: *UCI6FZ8LJ:?86=@D[F69+.UAM4EE8!6
MED2!%#RD*H+$9.!0!,EG;Q)!%'#$L5KC[-&L2*MN%B:%1 H&(L1.\8V@81BH
MPI((!6N-&TF[NH+ZYTVPGO;;'V>\GL[:6ZM]O*^3<21EX\'D8;CM0!<>WBD:
M)Y(T=X'\R%F56:*38\9DC)'R/Y<DB;EP=LC+G#$$ <88S(TNU5D9$C9PH#M'
M&79$9NI56D<@'IO;&-QR 9]UH>CWL$%K>Z7IUW;6N/LUO<V-K/!;[8_*3R89
MHF2+;'\HV* !P..* +$6GVENL*000P"UB:"V$44:"WMV,9:" *H$4)\J+*+A
M3Y29'R#  ^*SMH'62*&)7C6=481H'07,JSW 5PN5$LR)))@_.ZAFR0* &M86
MAD:;R(?-:59VD\J,N9TB6W2<MMR9E@41!SE@@V@A1B@"P\221F*0!D92KJP!
M5U*E65E/!4J2"#ZT ."A5"#Y0H"@#C 48  'L* ,6'PUX?M;S^T+?1-(M[\2
I2S?;H--LHKSSI]XFE^U)")?,D#N&8-E@[ D[C0!N4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
